We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Allena Pharmaceuticals Inc | NASDAQ:ALNA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.075 | 0.0825 | 0.0832 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 15, 2022 |
Allena Pharmaceuticals, Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware |
001-38268 |
45-2729920 |
||
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
One Newton Executive Park Suite 202 |
|
|||
Newton, Massachusetts |
|
02462 |
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (617) 467-4577 |
Not Applicable |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
Common Stock, par value $0.001 per share |
|
ALNA |
|
The Nasdaq Stock Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 1.02 Termination of a Material Definitive Agreement.
On June 15, 2022, Allena Pharmaceuticals, Inc. (the “Company”) delivered written notice to terminate its Commercial Lease (the “Lease”) with Cummings Properties, LLC (the “Lessor”), under which the Company currently occupies approximately 6,055 square feet of office space at One Newton Executive Park, Suite 202, in Newton, Massachusetts, which is currently the location of the Company’s principal executive offices. The Lease will terminate effective July 31, 2022.
Beginning on August 1, 2022, the Company’s principal executive offices will be located at 142-F North Road, Suite 150, Sudbury, Massachusetts 01776.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Allena Pharmaceuticals, Inc. |
|
|
|
|
Date: |
June 22, 2022 |
By: |
/s/ Richard Katz |
|
|
|
Richard Katz, M.D. |
1 Year Allena Pharmaceuticals Chart |
1 Month Allena Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions